Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
14.50    0.00 (0.00%)
Bid:
14.00
Ask:
15.00
Spread: 1.00 (7.143%)
Market Cap: £11.97m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Exercise of Options & Total Voting Rights

14 Sep 2023 07:00

RNS Number : 3747M
Frontier IP Group plc
14 September 2023
 

AIM: FIPP

14 September 2023

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Exercise of Options, Issue of Equity

and

Total Voting Rights

 

Frontier IP, a specialist in commercialising intellectual property, announces that it has issued and allotted 47,000 ordinary shares of 10 pence each in the Group (the "New Ordinary Shares") following an exercise of 47,000 options on 13 September 2023. The options have been exercised as follows:

 

Grant Date

Number of Options

Exercise Price

11 May 2017

47,000

40 pence

 

The New Ordinary Shares have been issued pursuant to the exercise of options granted to an employee under the Frontier IP Group plc Employee Share Option Scheme 2011. The New Ordinary Shares rank, pari passu, in all respects with the Company's existing ordinary shares of 10p each ("Ordinary Shares"). 

 

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 47,000 New Ordinary Shares to trading on AIM will become effective on, or around, 21 September 2023 ("Admission").

 

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 55,734,553 Ordinary Shares, with one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be 55,734,553. From Admission, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 020 3968 7815

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Harry Gooden / James Fischer

 

 

T: 0207 496 3000

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

 

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUGWBUPWGMW
Date   Source Headline
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSUnaudited Half Year Results
24th Mar 20257:00 amRNSCamGraphIC secures €25 million in Series A funding
18th Mar 20257:00 amRNS-RPulsiv wins PSMA’s Global Energy Efficiency Award
25th Feb 20257:00 amRNS-RGraphEnergyTech collaboration & Innovate UK grant
18th Feb 20257:00 amRNS-RTopps Tiles launches Alusid’s Mas floor tiles
31st Dec 20241:30 pmRNSTotal Voting Rights
30th Dec 20249:56 amRNSHolding(s) in Company
20th Dec 20247:00 amRNSGrant of Options
19th Dec 20244:14 pmRNSResult of AGM
29th Nov 20245:00 pmRNSTotal Voting Rights
29th Nov 20241:36 pmRNSHolding(s) in Company
27th Nov 20247:00 amRNSPosting of Circular & Annual Report, & AGM Notice
26th Nov 20247:00 amRNSResult of Retail Offer
22nd Nov 20241:31 pmRNSResult of Placing and Subscription
22nd Nov 20248:12 amRNSRetail Offer by PrimaryBid
22nd Nov 20247:01 amRNSProposed Placing and Subscription
22nd Nov 20247:00 amRNSFinal results for the year ended 30 June 2024
29th Oct 20244:45 pmRNSHolding(s) in Company
11th Sep 202412:10 pmRNSHolding(s) in Company
7th Aug 20243:52 pmRNSHolding(s) in Company
6th Aug 20243:47 pmRNSHolding(s) in Company
28th Jun 20247:00 amRNSPortfolio – Cambridge Raman Imaging loan facility
19th Jun 20247:00 amRNSHolding(s) in Company
24th May 20247:00 amRNSTopps Group’s arm launches Alusid floor tile range
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.